Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
137
resultados
Última actualización
03/08/2025 [07:19:00]
Resultados 25 a 50 de 137
Resumen de: WO2025121789A1
The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.
Resumen de: WO2025120137A1
The present invention relates to the field of mucins and mRNA isoforms thereof, more in particular the use of mucins and mRNA isoforms in subjects suspected having an intestinal disorder. Provided herein is an in vitro method for determining the presence of barrier damage to the intestinal tract and/or prediction of therapy response and recovery thereto by determining the expression of at least 3 mRNA isoforms originating from genes selected from the list comprising: MUC1, MUC2, MUC3A, MUC4, MUC5AC, MUC5B, MUC6, MUC12, MUC12-AS1, MUC13, MUC16, MUC17, MUC19, MUC20 or an overlapping transcript or a pseudogene thereof.
Resumen de: CN113645846A
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: US2025177779A1
In some embodiments, the present disclosure relates to a method. The method includes extracting a plurality of pre-treatment features from one or more first regions of interest (ROI) within pre-treatment imaging data. Prognostic pre-treatment features are identified from the plurality of pre-treatment features. The prognostic pre-treatment features are determinative of a treatment response. A plurality of post-treatment features are extracted from one or more second ROI within post-treatment imaging data. Prognostic post-treatment features are extracted from the plurality of post-treatment features. The prognostic post-treatment features are determinative of the treatment response. Prognostic tumor diversity features are determined from a common subset of the prognostic pre-treatment features and the prognostic post-treatment features. A machine learning stage is operated to generate a medical prediction of the treatment response for a bowel cancer patient using the prognostic tumor diversity features.
Resumen de: US2025180579A1
Methods for identifying sensitivity to what in an individual are provided, in which a sample from the individual is characterized for the presence of antibodies reactive with a whole wheat antigen and differentially characterizes for antibodies reactive with transglutaminase-2, transglutaminase-3, and transglutaminase-6. The presence of antibodies reactive with other wheat antigens, including α-gliadin, native γ-gliadin, native {acute over (ω)}-gliadin, and glutenin can also be characterized.
Resumen de: US2020262889A1
Polypeptides comprising an amino acid sequence of Slc26a6 or IRBIT comprising a mutation that increases NaDC-1 binding, stability of the polypeptide, stability of NaDC-1 complex or a combination thereof are provided. Polypeptides comprising an amino acid sequence of a mutant succinate receptor 1 (mutSUCNR1), comprising a mutation that increases succinate binding, stability of the polypeptide, stability of the mutSUCNR1-succinate complex or combinations thereof are also provided. Compositions comprising the polypeptides, nucleic acid molecules and vectors encoding the polypeptides, and methods of use of the polypeptides or compositions, specifically for treating succinate-associate diseases and conditions are also provided.
Resumen de: WO2025117950A1
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Resumen de: WO2025114553A1
The present invention refers to an in vitro method for diagnosing or screening a chronic inflammatory disease selected from the group comprising: Inflammatory bowel disease (IBD), arthritis or psoriasis.The present invention also refers to an in vitro method for monitoring patients suffering from a chronic inflammatory disease selected from the group comprising: IBD, arthritis or psoriasis; and/or for differentiating active patients suffering from a chronic inflammatory disease selected from the group comprising: IBD, arthritis or psoriasis from those patients who are in remission.
Resumen de: EP4564005A1
The present invention refers to an in vitro method for diagnosing or screening a chronic inflammatory disease selected from the group comprising: Inflammatory bowel disease (IBD), arthritis or psoriasis.
Resumen de: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Resumen de: WO2025109034A1
The present invention relates to a method of determining or predicting the sensitivity of a subject to an anti-inflammatory treatment against IBD using vedolizumab, comprising the steps of: Providing a biological sample of a subject suffering from IBD, determining the methylation status of at least one CpG selected from the group consisting of cg08081727, cg17830959, cg03455316, cg05197062, cg00441209, cg00706914, cg12906381, cg25299227, cg05338672, cg17764313, cg16467921, cg04674762, cg02601475, cg14115807, cg21070860, cg04546413, cg12667521, cg05062694, cg02229781, cg17096289, cg08017465, cg18319102, cg09659072, cg03161606, cg25267487, and determining the sensitivity based on said methylation status wherein a higher level of methylation of cg17830959, cg03455316, cg25299227, cg05197062, cg12906381, cg05338672, cg02601475, cg00706914, cg04674762, cg02229781, cg09659072, cg08017465, cg18319102, cg21070860, cg14115807, and a lower level of methylation of cg08081727, cg00441209, cg17764313, cg16467921, cg05062694, cg25267487, cg03161606, cg04546413, cg17096289, cg12667521 in comparison to a control value or control sample is indicative of an increased sensitivity to a therapy using vedolizumab.
Resumen de: WO2025109148A1
The invention relates to methods for diagnosing inflammatory bowel disease (IBD) and for distinguishing between common gastrointestinal disease (principally functional bowel disease/irritable bowel syndrome and coeliac disease) and IBD, especially in children and in subjects with normal levels of C-reactive protein. The methods are based on measuring the methylation level of at least one CpG site in at least one gene.
Resumen de: CN120072156A
The invention discloses an ulcerative colitis severity assessment method and system, and relates to the technical field of artificial intelligence, and the method comprises the following steps: data collection and ulcerative colitis symptom classification; preliminarily evaluating the severity of ulcerative colitis according to clinical data; performing correlation analysis based on the preliminary evaluation model and the severity score; performing intelligent diagnosis according to the combination of the severity score and the real-time physiological monitoring data; personalized treatment scheme recommendation is carried out according to the intelligent diagnosis result; evaluating the recovery progress of the patient by using the personalized treatment scheme; performing subsequent illness state prediction according to the recovery progress data; and a long-term monitoring scheme is provided for future disease course management based on a disease prediction result. According to the method, an improved regression analysis method is provided, and a nonlinear term, an interaction effect and a dynamic adjustment mechanism are introduced, so that the model can better capture a nonlinear complex relationship in clinical data, and the prediction precision is remarkably improved.
Resumen de: CN120077274A
Provided herein is a method for inspecting irAE enteritis, comprising a detection step for detecting an antibody that immunologically reacts with a fragment or all of integrin alpha v beta 6 in a sample as an indicator of ulcerative colitis-like irAE enteritis.
Resumen de: CN120072056A
The invention provides application of intestinal flora as a marker in preparation of a product for evaluating the treatment effect of inflammatory bowel diseases. The feasibility of predicting the curative effect of the medicine for treating the inflammatory bowel disease patient by using the microbial spectrum can accurately discriminate the patient needing to optimize the treatment scheme in the early stage of the disease, so that the prognosis condition of the patient is remarkably improved. Meanwhile, the invention provides a construction method of an intestinal flora biomarker prediction model, accurate prediction of the ineffective condition of drug treatment is realized through the combination of faecobacteria prausnitzii, Blauratia massiensis and coma faecalis, and the potential of the intestinal flora biomarker prediction model as a new tool for early recognition of a patient possibly needing optimized treatment is highlighted.
Resumen de: CN120041371A
The invention relates to the technical field of cell biology, in particular to a construction method and application of intestinal organs for children with Crohn's disease, the intestinal organs for children with Crohn's disease are successfully constructed by utilizing intestinal tissues from children with Crohn's disease, and the intestinal organs have various characteristic cells of the intestinal tissues; besides, immune cells are extracted from peripheral blood of a child patient homologous with intestinal tissues, a co-culture system is established with the organ-like model, the intestinal immune microenvironment of the child patient suffering from the Crohn's disease can be reproduced, and the system provides a new model for related mechanism exploration and drug screening of the child Crohn's disease.
Resumen de: PH12022550223A1
Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.
Resumen de: CN120047411A
The invention provides a method for assisting in identifying ulcerative colitis inflammatory activity levels based on dynamic graph multi-instance learning. The method comprises the steps of data acquisition, data preprocessing, dynamic graph multi-instance learning model construction of inflammatory activity level diagnosis and model evaluation. The data acquisition mainly comprises the steps of collecting pathological images of a patient with ulcerative colitis, digitalizing the pathological images through a digital scanner, excluding a part of pathological images containing problems such as blurring, fading and abnormal staining, and finally determining a grading label of each pathological image by a deep gastrointestinal pathology expert. The data preprocessing mainly comprises the steps of processing a digital pathological image, converting the digital pathological image into image blocks, then extracting features from each image block by using a visual basic model, and finally constructing a dynamic graph multi-instance learning model for training. According to the method, exploration of the internal relation of the image blocks input to the WSI is promoted, and the prediction effect of the model is improved.
Resumen de: CN120026084A
The invention belongs to the technical field of biological medicine, and particularly relates to a target spot for photodynamic treatment of ulcerative colitis and application of the target spot. According to the invention, LD4 is used for treating ulcerative colitis for proteomics research, then a Lasso machine learning algorithm is used for screening key targets, and it is found that the expression quantity of EPHX2 protein has significant correlation with ulcerative colitis, so that the EPHX2 protein can be used as a biomarker of ulcerative colitis. According to the application disclosed by the invention, the Pearson correlation calculation principle is used for analysis to find that the EPHX2 protein and the memory B cells have extremely remarkable correlation, and the infiltration amount of various immune cells is controlled by inhibiting the expression of the EPHX2 protein, particularly the abnormal increase of the memory B cells in the intestinal inflammation period is inhibited, so that the inflammation is promoted to gradually subside. Through analysis of a working characteristic curve of a subject, the kit is found to have excellent clinical sensitivity and specificity. The invention provides a new target for researching a novel medicine for treating ulcerative colitis, also provides a detection target for diagnosing ulcerative colitis, and has a good application prospect.
Resumen de: EP4285988A2
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Resumen de: CN120015247A
The invention belongs to the technical field of medical auxiliary diagnosis, and discloses an ulcerative colitis virtual biopsy method and system based on a multi-modal image, and the method comprises the steps: building an ulcerative colitis medical image database; constructing a prediction data set according to the extracted quantitative features and the pathological grades of the ulcerative colitis patients; based on the prediction data set, constructing and training an ulcerative colitis virtual biopsy model; and acquiring new clinical data of a patient with ulcerative colitis in real time, inputting the acquired new clinical data into the trained ulcerative colitis virtual biopsy model, and outputting a pathological grading result of ulcerative colitis through extraction and prediction of pathological features. According to the method, automatic analysis of image and endoscopic image features of the lesion area can be realized, the pathological activity state of the ulcerative colitis patient can be accurately judged, and association with long-term prognosis of the patient is established, so that help is provided for clinicians to formulate an individualized UC treatment scheme.
Resumen de: US2025154591A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
Resumen de: US2025154215A1
The present invention relates to a dual PRR-inhibiting peptide system consisting of TLR4- and RAGE-inhibiting motifs derived from S100A8 and S100A9 and conjugated with a CT peptide for colon-specific delivery. In human-derived monocyte THP-1 and mouse bone marrow-derived macrophages (BMDMs), S100A8/A9-derived peptides including TLR4 and RAGE-interacting motifs inhibit the binding of S100 to TLR4 or RAGE and the activation of the NLRP3 inflammasome in a dose-dependent manner. When the peptide according to the present invention is injected into mouse models of acute and chronic colitis, survival is significantly increased, and pathological damage to the colon is alleviated. In a mouse model of colitis-related colorectal cancer, when the peptide according to the present invention is injected, body weight is increased, tumor burden in the distal colon is decreased, and histological colon damage is significantly alleviated. When the peptide according to the present invention is injected into an oxaliplatin-resistant CRC xenograft mouse model, EMT-associated markers are reduced in tumor tissues and tumor growth is significantly inhibited.
Resumen de: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Nº publicación: EP4551599A1 14/05/2025
Solicitante:
NORDIC BIOSCIENCE AS [DK]
Nordic Bioscience A/S
Resumen de: CN119546632A
The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.
BOPI
Sede Electrónica
